Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spero TherapeuticsSPRO -3.15% 3-Year Book Growth Rate is -10.30% as of Mar. 2026. The stock has 4 warning signs investors should review. Among 1,131 Biotechnology companies, Spero Therapeutics ranks worse than 51.46% on this metric.
During the past 12 months, Spero Therapeutics's average Book Value per Share Growth Rate was 51.10% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -10.30% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -25.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Spero Therapeutics was -8.50% per year. The lowest was -32.30% per year. And the median was -24.75% per year.
Spero Therapeutics (NAS:SPRO) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Spero Therapeutics 3-Year Book Growth Rate Related Terms
SPRO vs ACRV, BSEM, RNTX: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Spero Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's 3-Year Book Growth Rate falls into.
Spero Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -10.30% mean?
Spero Therapeutics (SPRO) has a 3-Year Book Growth Rate of -10.30% as of Mar. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Spero Therapeutics and its competitors. According to the industry distribution chart, Spero Therapeutics ranks #582 out of 1131 companies in the Biotechnology industry, placing it in the top 51.5%.
Is Spero Therapeutics' 3-Year Book Growth Rate too high?
Spero Therapeutics' current 3-Year Book Growth Rate is -10.30%. Based on the distribution chart, Spero Therapeutics ranks #582 out of 1131 companies in the Biotechnology industry, which is below the industry midpoint.
How does Spero Therapeutics' 3-Year Book Growth Rate compare to ACRV and BSEM?
According to the Biotechnology industry distribution chart, Spero Therapeutics ranks #582 out of 1131 companies for 3-Year Book Growth Rate. This places Spero Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Spero Therapeutics and its competitors. Spero Therapeutics's current 3-Year Book Growth Rate is -10.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $1.24 — trading 18.1% above its estimated fair value. The current 3-Year Book Growth Rate is -10.30%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current 3-Year Book Growth Rate is -10.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRO has been successfully added to your 
